SciSparc Issued Israeli Patent for its Core Technology for Treating Central Nervous Systems Disorders
August 12 2022 - 8:00AM
SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage
pharmaceutical company focusing on the development of therapies to
treat disorders of the central nervous system (the “Company” or
“SciSparc”), today announced it has been granted an Israeli patent
for its core technology that treats central nervous systems
disorders. The invention relates to "Pharmaceutical compositions
comprising cannabinoids and N-acylethanolamines, and methods for
their use in preventing and treating a variety of
cannabinoid-treatable conditions."
“Our IP portfolio continues to grow, and it is
one of our greatest and most important assets which distinguishes
us from other companies operating in the field,” said Adi
Zuloff-Shani, PhD, Chief Technologies Officer of SciSparc. “This is
now the fifth recent patent grant we have received related to our
core technology, with patents previously issued in the U.S.,
Australia and Japan. This grant further solidifies the strength of
our intellectual property protections and aligns well with our
overarching patent filing strategy."
About SciSparc
(NASDAQ:SPRC):
SciSparc Ltd. is a specialty clinical-stage
pharmaceutical company led by an experienced team of senior
executives and scientists. Our focus is on creating and enhancing a
portfolio of technologies and assets based on cannabinoid
pharmaceuticals. With this focus, the Company is currently engaged
in the following drug development programs based on THC and/or
non-psychoactive cannabidiol (CBD): SCI-110 for the treatment of
Tourette Syndrome and for the treatment of obstructive sleep apnea;
SCI-160 for the treatment of pain; and SCI-210 for the treatment of
autism spectrum disorder and epilepsy.
Forward-Looking Statements:
This press release contains forward-looking
statements within the meaning of the "safe harbor" provisions of
the Private Securities Litigation Reform Act of 1995 and other U.S.
federal securities laws. For example, SciSparc is using
forward-looking statements when it discusses its patent filing
strategy and its potential to bring therapies to patients suffering
with the challenges associated with disorders of the central
nervous system. Because such statements deal with future events and
are based on SciSparc's current expectations, they are subject to
various risks and uncertainties and actual results, performance or
achievements of SciSparc could differ materially from those
described in or implied by the statements in this press release.
The forward-looking statements contained or implied in this press
release are subject to other risks and uncertainties, including
those discussed under the heading "Risk Factors" in SciSparc's
Annual Report on Form 20-F filed with the U.S. Securities and
Exchange Commission (the "SEC") on April 28, 2022, and in
subsequent filings with the SEC. Except as otherwise required by
law, SciSparc disclaims any intention or obligation to update or
revise any forward-looking statements, which speak only as of the
date they were made, whether as a result of new information, future
events or circumstances or otherwise.
Logo
- https://mma.prnewswire.com/media/1434686/SciSparc_Ltd_Logo.jpg
Investor Contact:IR@scisparc.comTel:
+972-3-6167055
SciSparc (NASDAQ:SPRC)
Historical Stock Chart
From Mar 2024 to Apr 2024
SciSparc (NASDAQ:SPRC)
Historical Stock Chart
From Apr 2023 to Apr 2024